Skip to content

Comparative Safety of JAK versus TNF Inhibitors in Older Adults with Rheumatoid Arthritis: A Propensity Score-Matched Cohort Study.

Oct 2026 · Journal of Rheumatology · pp. jrheum.2026-0333 · 0 citations
Medicine

TL;DR

In this real-world cohort of older adults with RA, initiation of JAK inhibitors was not associated with higher risks of MACE, VTE, malignancy, or mortality compared with TNF inhibitors.

Abstract

Objective

This study evaluated the comparative safety of Janus kinase inhibitors (JAKi) vs tumor necrosis factor inhibitors (TNFi) among older adults aged ≥65 years with rheumatoid arthritis (RA), including a prespecified subgroup of patients aged ≥75 years.

Methods

A retrospective cohort study was conducted using the TriNetX U.S. Collaborative Network. Adults aged ≥65 years with RA who initiated JAKi or TNFi between 2016 and 2023 were included. Propensity score matching (1:1) was used to balance demographics, comorbidities, medications, and healthcare utilization. Patients were followed for up to 3 years. Primary outcomes were venous thromboembolism (VTE) and major adverse cardiovascular events (MACE). Secondary outcomes included malignancy and all-cause mortality. Cox proportional hazards models estimated hazard ratios (HRs) with 95% confidence intervals (CIs). Sensitivity analyses using an as-treated (AT) design and a prespecified subgroup analysis of adults aged ≥75 years were performed.

Results

After matching, 1,304 patients remained in each group. Over 3 years, JAKi vs TNFi was not associated with increased risk of VTE (50 vs 43 events; HR 1.18, 95% CI 0.79-1.78), MACE (164 vs 148; HR 1.13, 95% CI 0.91-1.41), malignancy (63 vs 68; HR 0.94, 95% CI 0.66-1.32), or mortality (71 vs 66; HR 1.10, 95% CI 0.79-1.54). Findings were consistent in the ≥75-year subgroup and as-treated analyses.

Conclusion

In this real-world cohort of older adults with RA, initiation of JAK inhibitors was not associated with higher risks of MACE, VTE, malignancy, or mortality compared with TNF inhibitors.

View source

Similar papers

Oct 2026

Cardiovascular risk associated with first-line Janus kinase inhibitors versus TNF inhibitors in patients with RA: a nationwide cohort study.

First-line use of JAKi was not associated with an increased risk of MACE compared with TNFi, providing real-world evidence supporting the cardiovascular safety of JAKi as first-line advanced therapy in patients with RA.

O. C. Kwon, Hye Sun Lee, S. Jeon et al. · 0 citations
Open access Sep 2026

Cardiovascular and mortality outcomes with JAK versus TNF inhibitors in rheumatoid arthritis: a target trial emulation (CARDINAL-RA)

Objectives This study aims to compare cardiovascular and mortality outcomes of Janus kinase inhibitors (JAKi) versus tumor necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA) at elevated cardiovascular risk using target trial emulation. Methods Within TriNetX, adults with RA aged ≥50 years and ≥1 cardiovascu...

R. McClenahan, L. Alamlih · 0 citations
Nov 2026

Age-stratified risk of major adverse cardiovascular events with JAK inhibitors in rheumatoid arthritis: A nationwide cohort study.

BACKGROUND The cardiovascular safety of Janus kinase inhibitors (JAKi) compared with biological disease-modifying antirheumatic drugs (bDMARDs) and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in rheumatoid arthritis (RA) remains debated. We aimed to evaluate the risk of major adverse cardiov...

Chun-Hsin Wu, Chia-Tse Weng, Sheng-Hsiang Lin · 0 citations
Open access Sep 2026

Venous Thromboembolism Risk Following Total Joint Arthroplasty in Rheumatoid Arthritis Patients Treated with Janus Kinase Inhibitors Versus Tumor Necrosis Factor Inhibitors: A Propensity Score-Matched Cohort Study

Among RA patients undergoing primary TJA, JAK inhibitor use was not associated with a statistically significant increase in postoperative VTE compared with TNF inhibitor use, although VTE events occurred numerically more often in the JAK inhibitor cohort.

Rafaay Kamran, M. Chaudhary, Mark Herbert et al. · 0 citations
Open access Oct 2026

Effectiveness of Newly Initiated Tofacitinib and Biologic DMARDs in Patients with Rheumatoid Arthritis.

There were no statistically significant differences in CDAI remission and LDA rates between treatments at 6 and 12 months and potential HTE was observed among subgroups of age ≥ 50 years, obesity, prior b/tsDMARD use, corticosteroid use, and Sjӧgren's disease.

K. Liao, C. Gopalakrishnan, J. Yazdany et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.